

# Thomas R E Barnes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3508457/publications.pdf>

Version: 2024-02-01

69  
papers

5,758  
citations

126907

33  
h-index

95266

68  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4569  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Rating Scale for Drug-Induced Akathisia. <i>British Journal of Psychiatry</i> , 1989, 154, 672-676.	2.8	2,072
2	Syndromes of Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1990, 157, 558-561.	2.8	262
3	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2020, 34, 3-78.	4.0	259
4	Executive function in first-episode schizophrenia. <i>Psychological Medicine</i> , 1998, 28, 463-473.	4.5	241
5	Antipsychotic Polypharmacy in Schizophrenia. <i>CNS Drugs</i> , 2011, 25, 383-399.	5.9	171
6	The Nature and Prevalence of Depression in Chronic Schizophrenic In-patients. <i>British Journal of Psychiatry</i> , 1989, 154, 486-491.	2.8	157
7	The Barnes Akathisia Rating Scale—Revisited. <i>Journal of Psychopharmacology</i> , 2003, 17, 365-370.	4.0	150
8	South Westminster Schizophrenia Survey. <i>British Journal of Psychiatry</i> , 1994, 164, 630-636.	2.8	145
9	The relationship between negative symptoms and depression in schizophrenia: a systematic review. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 380-390.	4.5	133
10	The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. <i>Lancet Psychiatry</i> , 2018, 5, 885-894.	7.4	133
11	Cognitive functioning and symptomatology in chronic schizophrenia. <i>Psychological Medicine</i> , 1990, 20, 357-365.	4.5	126
12	Is the Concept of Frontal—Subcortical Dementia Relevant to Schizophrenia?. <i>British Journal of Psychiatry</i> , 1992, 160, 442-460.	2.8	120
13	Long Term Depot Antipsychotics. <i>Drug Safety</i> , 1994, 10, 464-479.	3.2	117
14	The Use of Psychotropic Medication in Patients With Emotionally Unstable Personality Disorder Under the Care of UK Mental Health Services. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e512-e518.	2.2	106
15	One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. <i>British Journal of Psychiatry</i> , 1997, 171, 564-568.	2.8	102
16	Akathisia: Prevalence and Associated Dysphoria in an In-patient Population with Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1994, 164, 177-183.	2.8	95
17	Antipsychotic long-acting injections: Prescribing practice in the UK. <i>British Journal of Psychiatry</i> , 2009, 195, s37-s42.	2.8	93
18	Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. <i>International Clinical Psychopharmacology</i> , 2007, 22, 238-243.	1.7	83

#	ARTICLE	IF	CITATIONS
19	Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. <i>Lancet Psychiatry</i> , 2018, 5, 633-643.	7.4	71
20	Treatment Recommendations for Tardive Dyskinesia. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 388-399.	1.9	52
21	Management of Treatment Resistant Schizophrenia Unresponsive to Clozapine. <i>British Journal of Psychiatry</i> , 1996, 169, 31-40.	2.8	51
22	Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 730-739.	1.9	51
23	The Safety and Efficacy of Clozapine in Severe Treatment-Resistant Schizophrenic Patients in the UK. <i>British Journal of Psychiatry</i> , 1993, 163, 150-154.	2.8	48
24	Cognitive Function and Duration of Rooflessness in Entrants to a Hostel for Homeless Men. <i>British Journal of Psychiatry</i> , 1996, 169, 434-439.	2.8	48
25	The Assessment and Treatment of Antipsychotic-Induced Akathisia. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 719-729.	1.9	48
26	Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. <i>British Journal of Psychiatry</i> , 2010, 197, 67-72.	2.8	46
27	Depression and the experience of psychological deficits in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1993, 88, 243-247.	4.5	45
28	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	11.0	44
29	Four Behavioural Syndromes of Schizophrenia. <i>British Journal of Psychiatry</i> , 1996, 168, 562-570.	2.8	40
30	Comment on the WHO Consensus Statement. <i>British Journal of Psychiatry</i> , 1990, 156, 413-414.	2.8	36
31	Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK. <i>BMJ Open</i> , 2015, 5, e007633.	1.9	36
32	Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. <i>Journal of Psychopharmacology</i> , 2008, 22, 323-329.	4.0	34
33	Lithium in bipolar and other affective disorders: prescribing practice in the UK. <i>Journal of Psychopharmacology</i> , 2010, 24, 1739-1746.	4.0	34
34	Antipsychotic-Induced Extrapyrarnidal Symptoms. <i>CNS Drugs</i> , 1996, 6, 315-330.	5.9	33
35	Relationship Between Iron Status and Chronic Akathisia in an In-patient Population with Chronic Schizophrenia. <i>British Journal of Psychiatry</i> , 1992, 161, 791-796.	2.8	31
36	Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation) <i>Tj ETQq0 0 0 rgB7/Overlock 10 Tf 50</i>		

#	ARTICLE	IF	CITATIONS
37	Institutionalism and Schizophrenia 30 Years on. <i>British Journal of Psychiatry</i> , 1992, 160, 230-241.	2.8	30
38	Monitoring lithium therapy: the impact of a quality improvement programme in the UK. <i>Bipolar Disorders</i> , 2013, 15, 865-875.	1.9	29
39	Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. <i>Brain, Behavior, and Immunity</i> , 2021, 91, 498-504.	4.1	28
40	Negative Symptoms as a Risk Factor for Tardive Dyskinesia in Schizophrenia. <i>British Journal of Psychiatry</i> , 1993, 163, 776-780.	2.8	27
41	Movement Disorder in Down's syndrome: A possible marker of the severity of mental handicap. <i>Movement Disorders</i> , 1996, 11, 395-403.	3.9	26
42	The clinical characteristics of schizophrenic patients consenting or not consenting to a placebo controlled trial of antipsychotic medication. <i>Human Psychopharmacology</i> , 1994, 9, 423-433.	1.5	25
43	Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting. <i>Acta Psychiatrica Scandinavica</i> , 2011, 124, 396-402.	4.5	25
44	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. <i>Health Technology Assessment</i> , 2016, 20, 1-46.	2.8	25
45	What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication. <i>Psychological Medicine</i> , 2017, 47, 2369-2378.	4.5	21
46	Change in neuroleptic prescribing practice. <i>Psychiatric Bulletin</i> , 1995, 19, 237-239.	0.3	20
47	Movement Disorder Associated with Antipsychotic Drugs: The Tardive Syndromes. <i>International Review of Psychiatry</i> , 1990, 2, 355-366.	2.8	18
48	Cognitive-behavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-144.	2.8	16
49	The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods. <i>Psychiatry Research</i> , 2018, 270, 869-879.	3.3	15
50	Dyspraxia and Agnosia in Schizophrenia. <i>Behavioural Neurology</i> , 1993, 6, 49-54.	2.1	14
51	Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 185-197.	2.7	11
52	Are socioenvironmental factors associated with psychotic symptoms in people with first-episode psychosis? A cross-sectional study of a West London clinical sample. <i>BMJ Open</i> , 2019, 9, e030448.	1.9	10
53	Criteria for Evaluating Improvement in Schizophrenia in Psychopharmacological Research (With) Tj ETQq1 1 0.784314 rgBT /Overlock	2.8	9
54	Antipsychotic Drug-Induced Movement Disorders: A Forgotten Problem?. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 717-718.	1.9	9

#	ARTICLE	IF	CITATIONS
55	The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 71.	1.6	8
56	Role of the Prescribing Observatory for Mental Health. <i>British Journal of Psychiatry</i> , 2012, 201, 428-429.	2.8	7
57	Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2). <i>Trials</i> , 2019, 20, 331.	1.6	7
58	Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-54.	2.8	7
59	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093790.	2.7	6
60	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093049.	2.7	6
61	Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. <i>Psychological Medicine</i> , 2022, , 1-10.	4.5	3
62	Antipsychotic Drug-Induced Movement Disorders: A Forgotten Problem?. <i>Canadian Journal of Psychiatry</i> , 2018, , 070674371877252.	1.9	2
63	Prescribing antipsychotic medication for adults with intellectual disability: shared responsibilities between mental health services and primary care. <i>BJPsych Bulletin</i> , 2022, 46, 311-315.	1.1	2
64	More haste less speed: A meta-analysis of thinking latencies during planning in people with psychosis. <i>Psychiatry Research</i> , 2017, 258, 576-582.	3.3	2
65	The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial. <i>Therapeutic Advances in Psychopharmacology</i> , 2022, 12, 204512532210908.	2.7	2
66	Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532199127.	2.7	1
67	Plus Ça change? Switching lithium preparations. <i>BJPsych Bulletin</i> , 2023, 47, 71-76.	1.1	1
68	Time to re-evaluate the risks and benefits of valproate and a call for action. <i>British Journal of Psychiatry</i> , 2022, 221, 711-713.	2.8	1
69	Handbook of Schizophrenia. Edited by H. A. Nasrallah, Volume 4, Psychosocial Treatment of Schizophrenia. Edited by M. I. Herz, S. J. Keith and J. P. Docherty Amsterdam: Elsevier. 1990. 419 pp. Gld 350.. <i>British Journal of Psychiatry</i> , 1992, 161, 436-437.	2.8	0